Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes

Abstract

Microthrombosis may be involved in the pathogenesis of cardiac microangiopathy due to diabetes. Recent studies have shown that fibrinogen-like protein 2 (fgl2) plays a pivotal role in microthrombosis in viral hepatitis, acute vascular xenograft rejection and cytokine-induced fetal loss syndrome. The current study was designed to examine the expression of fgl2 in microvascular endothelial cells and investigate the effects of microthrombi due to fgl2 on cardiac function and structure in rats with type 2 diabetes. Following induction of type 2 diabetes, 24 rats were observed dynamically. Fgl2 expression and related cardiac microthrombosis were examined. Local or circulating TNF-α was measured. Coronary flow (CF) per min was calculated as an index of cardiac microcirculation. Cardiac function and morphology were evaluated. It was found that Fgl2 was highly expressed in cardiac microvascular endothelial cells of rats with type 2 diabetes, which was promoted by local or circulating TNF-α. The Fgl2 expression was associated with cardiac hyaline microthrombosis. In parallel with the fgl2 expression, CF per min, cardiac diastolic or systolic function and cardiac morphology were aggravated to some extent. It was concluded that in rats with type 2 diabetes, microthrombosis due to fgl2 contributes to the impairment of cardiac diastolic or systolic function and morphological changes.

Keywords

fibrinogen-like protein 2 / type 2 diabetes / ischemic heart disease / microangiopathy / tumor necrosis factor-α / cardiac function

References

[1] BeckmanJ.A., GreagerM.A., LibbyP.. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA, 2002, 287(19): 2570-2581

[2] YaromR., ZirkinH., StammlerG., et al.. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol, 1992, 166(3): 265-270

[3] KohlerH.P., GrantP.J.. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med, 2000, 342(24): 1792-1801

[4] CarrM.E.. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications, 2001, 15(1): 44-54

[5] BoeriD., MaielloM., LorenziM.. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes, 2001, 50(6): 1432-1439

[6] LevyG.A., LiuM., DingJ., et al.. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol, 2000, 156(4): 1217-1225

[7] ChanC.W., ChanM.W., LiuM., et al.. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol, 2002, 168(10): 5170-5177

[8] DingJ.W., NingQ., LiuM.F., et al.. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: Tissue-specific expression of a novel fgl2 prothrombinase. J Virol, 1997, 71(12): 9223-9230

[9] MarsdenP.A., NingQ., FungL.S., et al.. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest, 2003, 112(1): 58-66

[10] GhanekarA., MendicinoM., LiuH., et al.. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol, 2004, 172(9): 5693-5701

[11] MendicinoM., LiuM., GhanekarA., et al.. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation, 2005, 112(2): 248-256

[12] ClarkD.A., DingJ.W., ChaouatG., et al.. The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans. Am J Reprod Immunol, 1999, 42(1): 37-43

[13] KnackstedtM.K., ZenclussenA.C., HertwigK., et al.. Th1 cytokines and the prothrombinase fgl2 in stress-tri ggered and inflammatory abortion. Am J Reprod Immunol, 2003, 49(4): 210-220

[14] ClarkD.A., FoersterK., FungL., et al.. The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod, 2004, 10(2): 99-108

[15] LuoJ., QuanJ., TsaiJ., et al.. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism, 1998, 47(6): 663-668

[16] DoolittleR.F.. The structure and evolution of vertebrate fibrinogen. Ann N Y Acad Sci, 1983, 408: 13-27

[17] LevyG.A., MarsdenP., ZhongR., et al.. Strategies to prevent thrombosis in xenotransplants. Transplant Proc, 1998, 30(5): 2458-2460

[18] NingQ., BrownD., ParodoJ., et al.. Ribavirin inhibits viral-induced macrophage production of TNF-α, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol, 1998, 160(7): 3487-3493

[19] ClarkD.A., ChaouatG., ArckP.C., et al.. Cytokine-dependent abortion in CBA × DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol, 1998, 160(2): 545-549

[20] ClarkD.A., DingJ.W., YuG., et al.. Fgl2 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2. Mol Hum Reprod, 2001, 7(2): 185-194

[21] LiuM., MendicinoM., NingQ., et al.. Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin: the role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J Immunol, 2006, 176(11): 7028-7038

[22] AldhahiW., HamdyO.. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep, 2003, 3(4): 293-298

[23] RaderD.J.. Inflammatory markers of coronary risk. N Eng J Med, 2000, 343(16): 1179-1182

[24] YagihashiS., WadaR., YamagishiS.. Diabetic microangiopathy: pathology and current understanding of its pathogenesis. Verh Dtsch Ges Pathol, 2002, 86: 91-100

[25] RublerS., DlugashJ., YuceogluY.Z., et al.. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 1972, 30(6): 595-602

[26] HambyR.I., ZoneraichS., ShermanL.. Diabetic cardiomyopathy. JAMA, 1974, 229(13): 1749-1754

[27] DhallaN.S., LiuX., PanagiaV., et al.. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res, 1998, 40(2): 239-247